<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02309762</url>
  </required_header>
  <id_info>
    <org_study_id>FB825CLCT01</org_study_id>
    <nct_id>NCT02309762</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of FB825 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Ascending Intravenous Doses of FB825</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fountain Biopharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fountain Biopharma Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and
      immunogenicity of single-ascending IV doses of FB825
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse events (AE)</measure>
    <time_frame>Up to day140</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory test results (hematology, coagulation, serum chemistry[including liver function tests], and urinalysis)</measure>
    <time_frame>Up to day140</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital sign measurements (systolic and diastolic blood pressures, heart rate, respiratory rate, and oral body temperature)</measure>
    <time_frame>Up to day140</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>12-lead ECG results</measure>
    <time_frame>Up to day140</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical examination findings</measure>
    <time_frame>Up to day140</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of PK parameters</measure>
    <time_frame>Pre-dose, 2, 3, 5, 14, 29, 85, and 140 day post-dose</time_frame>
    <description>Blood will be collected for the determination of serum FB825 concentrations, Cmax, Tmax, AUC, and terminal half-life.These parameters will be determined using non-compartmental methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total IgE serum concentrations</measure>
    <time_frame>pre-dose, 5, 14, 29, 85, and 140 day post-dose</time_frame>
    <description>Blood will be collected to measure serum IgE concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity (Anti-FB825 antibody in serum)</measure>
    <time_frame>pre-dose, 5, 14, 29, 85, and 140 day post-dose</time_frame>
    <description>Blood will be collected to measure Immunogenicity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>FB825</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 cohorts of subjects are planned to be dosed by IV injection, with single- ascending doses ranging from 0.003 - 10 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FB825</intervention_name>
    <description>FB825 will be supplied at a concentration of 20 mg/mL for a single dose IV injection</description>
    <arm_group_label>FB825</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Solution containing no active ingredients</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subject is male or female between 18 and 55 years of age, inclusive.

          2. All female subjects must have a negative serum pregnancy test at screening and on Day
             −1.

          3. The subject has a body weight ≥50 kg at screening and a body mass index of 18 to 30
             kg/m2, inclusive.

          4. The subject has a good health condition based upon the results of medical history,
             physical examination, vital signs, laboratory profile and ECG.

          5. The subject has a negative urine drug screen for alcohol, cotinine.

        Exclusion Criteria:

          1. Female subjects who are pregnant or lactating.

          2. The subject has a past history of heart arrhythmias.

          3. The subject has history of clinically significant diseases.

          4. The subject has any history of a previous anaphylactic reaction.

          5. Use of prescribed medication within 6 months of Day −1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2014</study_first_submitted>
  <study_first_submitted_qc>December 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2014</study_first_posted>
  <last_update_submitted>February 3, 2016</last_update_submitted>
  <last_update_submitted_qc>February 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

